Videos

  
Panelists debate the use of alemtuzumab in multiple sclerosis, weighing the high efficacy vs the high frequency of autoimmune complications and serious adverse events.
The chief medical advisor for the Muscular Dystrophy Association detailed his experience with the process of having to manage patients and conduct research amid the COVID-19 pandemic.
Alon Y. Avidan, MD, MPH, outlines the signs and symptoms of narcolepsy, including excessive daytime sleepiness, cataplexy, sleep paralysis, hallucinations, and insomnia, as well as the challenges in diagnosis.
The chief medical advisor for the Muscular Dystrophy Association spoke about the process of keeping patients updated on new information and how the MDA has taken steps to ensure the neuromuscular community gets the correct information.
The Director of the Sleep Disorders Center and vice chair of the department of neurology at the UCLA David Geffen School of Medicine detailed how patients and physicians can be proactive in identifying narcolepsy.
In episode 10, Clyde Markowitz, MD, reflects on the importance of a standardized MRI protocol in light of the ACTRIMS 2020 meeting.
The chief medical advisor for the Muscular Dystrophy Association discussed how his approach to the management and care of patients with neuromuscular disease has been affected by the COVID-19 pandemic.
Expert sleep specialists give an overview of narcolepsy, including the 2 types, causes, prevalence, and use of a sleep diary.
A discussion of the EXPAND phase III clinical trial of the selective S1P receptor modulator siponimod for treatment of multiple sclerosis.
SAP Partner Banner